- In April 2025, Eli Lilly announced groundbreaking Phase 3 results for its oral GLP‑1 agonist orforglipron, showing comparable weight loss (~7.6–8% body weight) and improved HbA1C to injectables—but via a convenient daily pill. This marks the first oral alternative to semaglutide/Ozempic, with FDA submissions expected by late 2025
- In June 2025, Eli Lilly received approval in China for mazdutide (IBI362), a dual GLP‑1/glucagon agonist. Phase 3 data showed significant weight reductions in Chinese adults with overweight or obesity, reinforcing global momentum for advanced weight-loss biologics
- In May 2025, Amgen introduced MariTide, a once‑monthly GLP‑1 therapy, following trial results showing up to 16% weight loss over one year. Monthly injection schedules may enhance adherence compared to weekly options
- In April 2025, Pfizer discontinued its oral GLP‑1 candidate danuglipron after an unpredictable liver toxicity was observed in clinical trials, highlighting ongoing safety challenges in oral obesity drug development
- In May 2025, GLP‑1 prescriptions for weight management continued their steep rise in the U.S., with analysts projecting the obesity drug market to hit USD 100 billion by 2030. Wegovy, Saxenda, and Zepbound account for most current sales
